Otilimab anti-GM-CSF versus Sarilumab ou placebo chez des patients atteints de polyarthrite rhumatoïde et avec une réponse inadéquate aux thérapies ciblées : Un essai randomisé de phase III (contRAst 3)
Ann Rheum Dis. 2023;82(12):1527–1537 doi 10.1136/ard-2023-224449
The ContRAst 3 study investigated otilimab, in RA patients with inadequate responses to multiple treatments. Otilimab did not significantly improve ACR20 versus placebo at Weeks 12 or 24. In addition, there we no significant improvements in secondary endpoints, including disease activity, disability, and pain.